GeroScience Review Reframes Chronic Subdural Hematoma as a Hallmark-Driven Aging Pathology

A literature review published in GeroScience maps the pathogenesis of chronic subdural hematoma onto the 12 hallmarks of aging, identifying cellular senescence and chronic inflammation as potential targets for non-surgical gerotherapeutic interventions.

A minireview published in the journal GeroScience reframed chronic subdural hematoma (CSDH)—which is projected to become the most common cranial neurosurgical condition in adults by 2030—using the 12 hallmarks of aging framework.

The author reported that chronic inflammation and altered intercellular communication have strong direct support in the existing CSDH literature, manifesting as 'inflammaging' fingerprints in hematoma fluid.

Cellular senescence was identified as a moderate-evidence hallmark; while the molecular signature of the senescence-associated secretory phenotype (SASP) overlaps with the CSDH fluid profile, senescent cells have not yet been directly demonstrated in resected outer neomembrane tissue.

Other hallmarks, such as disabled macroautophagy and dysbiosis, have received initial direct measurements but remain only partially addressed in the literature.

CSDH has historically been managed primarily as a mechanical and surgical emergency of older adults.

Framing the condition through geroscience suggests that medical, mechanism-directed interventions—including statins, middle meningeal artery embolization, and emerging senolytics—could offer non-surgical therapeutic pathways.

Establishing cellular senescence as a driver of CSDH neomembrane inflammation could expand the clinical pipeline for senolytic drug developers.

By positioning the most common neurosurgical condition of older adults as a geroscience-tractable disease, this framework may incentivize clinical-stage longevity biotech companies to explore acute and subacute localized neuroinflammatory indications.

Successful translation of senolytic or autophagy-targeting molecules into CSDH would represent a significant expansion of the addressable market for these platforms beyond chronic age-related systemic diseases.

Future translational research and histopathological studies specifically designed to identify and verify the presence of senescent cell populations in resected neomembrane tissues.